Management of Pediatric Pneumococcal Diseases in the Era of the Pneumococcal Conjugate Vaccine
A supplement to Pediatric News.
Sponsored by Boston University School of Medicine and supported by an unrestricted educational grant from Wyeth.
Highlights of articles based on clinical dialogues with the faculty.
To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 14.
Faculty
Jerome O. Klein, MD
(Co-Chair)
Professor of Pediatrics
Vice Chairman for Academic Affairs
Boston University School of Medicine
Boston Medical Center Grant/Research Support: Wyeth; Consultant: Abbott, Bristol-Myers Squibb, Pfizer and Wyeth.
Management of Acute Otitis Media in the Era of Drug Resistance
Elizabeth Barnett, MD
Associate Professor of Pediatrics
Boston University School of Medicine Grant/Research Support: GlaxoSmithKline; Speaker's Bureau: Pfizer, Inc.
The Febrile Child and Invasive Pneumococcal Diseases
Larry Culpepper, MD, MPH
Professor and Chairman
Department of Family Medicine
Boston University School of Medicine Consultant: Abbott Laboratories, Eli Lilly and Company, Forest Laboratories, Janssen Pharmaceutica, Pfizer, Inc., and Wyeth.
Pneumonia and Otitis Media: The Northern California Data in Perspective
Henry Shinefield, MD
Co-Director
Kaiser Permanente Vaccine Study
Oakland, Calif. Grant/Research Support and Speaker's Bureaus: Aventis, Chiron, GlaxoSmithKline, Merck, and Wyeth; Consultant: Wyeth.
Vaccine Efficacy: Where Are the Gaps?
Stephen I. Pelton, MD
Professor of Pediatrics
Boston University School of Medicine
Director, Pediatric Infectious Diseases
Boston Medical Center Grant/Research Support: Wyeth, Apovia, Aventis, and GlaxoSmithKline; Consultant: Wyeth; Speaker's Bureaus: Wyeth and GlaxoSmithKline.
Target Audience
This activity has been developed for pediatricians, primary care physicians, and other health care professionals involved in the treatment of infectious diseases in children.
Educational Needs
Since the introduction of the heptavalent pneumococcal conjugate vaccine (PCV-7) in the United States in 2000, the number of cases of invasive pneumococcal disease has declined significantly. This decline has been documented by three large studies, including the Active Bacterial Core Surveillance program, part of the U.S. Centers for Disease Control and Prevention's Emerging Infections Program Network. These studies show that vaccination confers protection on vaccinated children, but they also support the theory of herd immunity in that the rate of pneumococcal infections has dropped in whole study populations, not just among vaccinated groups.
Along with the good news about declining rates of pneumococcal disease, the epidemiologic evidence that has accumulated prior to and since the introduction of the vaccine presents clinicians with practical challenges in managing those pediatric patients who may have pneumococcal disease despite vaccination. This supplement focuses on treatment issues within the context of widespread use of the PCV-7.
Learning Objectives
By reading and studying the articles in this supplement, participants should be able to discuss:
• The rationale use of antibiotics for patients with otitis media, given the changing trends and emerging geographic variations in resistance patterns of pneumococci and other causative organisms;
• Evidence-based management of the febrile child who may have invasive pneumococcal disease;
• The most recent data on the effect of the PCV-7 on pneumonia and otitis media from the large database accumulated by the Northern California Kaiser Permanente investigators;
• Which children are still at increased risk for pneumococcal disease.
Accreditation
Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Boston University School of Medicine designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that h/she actually spent on the activity.
In order to successfully complete this activity, you are required to read the entire monograph and complete and submit the completed test answer sheet by October 31, 2004. CME credit will be awarded provided a score of 70% or better is achieved. A certificate of credit will be sent within six weeks of receipt of the test answers to those who successfully complete the examination.
